Follicular lymphoma international prognostic index

Blood

Volumn 104, Issue 5, 2004, Pages 1258-1265

  Solal Céligny, Philippe ^a   Roy, Pascal ^b   Colombat, Philippe ^b   White, Josephine ^b   Armitage, Jim O ^b   Arranz Saez, Reyes ^b   Au, Wing Y ^b   Bellei, Monica ^b   Brice, Pauline ^b   Caballero, Dolores ^b   Coiffier, Bertrand ^b   Conde Garcia, Eulogio ^b   Doyen, Chantal ^b   Federico, Massimo ^b   Fisher, Richard I ^b   Garcia Conde, Javier F ^b   Guglielmi, Cesare ^b   Hagenbeek, Anton ^b   Haïoun, Corinne ^b   LeBlanc, Michael ^b   Lister, Andrew T ^b   Lopez Guillermo, Armando ^b   McLaughlin, Peter ^b   Milpied, Noël ^b   Morel, Pierre ^b   Mounier, Nicolas ^b   Proctor, Stephen J ^b   Rohatiner, Ama ^b   Smith, Paul ^b   Soubeyran, Pierre ^b   Tilly, Hervé ^b   Vitolo, Umberto ^b   Zinzani, Pier Luigi ^b   Zucca, Emanuele ^b   Montserrat, Emili ^b   more..

^a CENTRE JEAN BERNARD   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGE; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; HEMOGLOBIN DETERMINATION; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE COUNT; VALIDATION PROCESS;

EID: 4444326818     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4434     Document Type: Article

References (34)

1. Horning ST. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-80.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
3. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients: a study of the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1999;17:2499-2505.
4. Leonard RCF, Hayward RL, Prescott RJ, et al. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma: The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol. 1991;2:655-662.
5. Cameron DA, Leonard RCF, Mao J-H, et al. Identification of prognostic groups in follicular lymphoma. Leuk Lymphoma. 1993;10:89-99.
6. Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1994;10:489-492.
7. Denham JW, Denham E, Dear KB, et al. The follicular non-Hodgkin's lymphomas, II: prognostic factors: what do they mean? Eur J Cancer. 1996;32A:480-490.
8. Soubeyran P, Eghbali H, Bonichon F, et al. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer. 1991;27:1606-1613.
9. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood. 2000;95:783-789.
10. Maartense E, Le Cessie S, Kluin-Nelemans HC, et al. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. Ann Oncol. 2002;13:1275-1284.
11. Steward WF, Crowther D, McWilliam LJ, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. Cancer. 1988;61:441-447.
12. Romaguera JE, McLaughlin P, North L, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol. 1991;9:762-769.
13. Bastion Y, Berger F, Bryon PA, et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol. 1991;2(suppl 2):123-134.
14. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Am J Med. 1991;114:855-860.
15. Coiffier B, Bastion Y, Berger F, et al. Prognostic factors in follicular lymphomas. Semin Oncol. 1993;5(suppl 5):89-95.
16. Hermans J, Krol ADG, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood. 1995;86:1460-1463.
17. Lopez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International Prognostic Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol. 1994;12:1343-1348.
18. Avilès A. The International Index is not useful in the classification of low-grade lymphoma. J Clin Oncol. 1994;12:2766-2770.
19. Bastion Y, Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol. 1994;12:1340-1342.
20. Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? applicability to stage III-IV patients. Ann Oncol. 1997;8(suppl 1):S49-S52.
21. Non-Hodgkin's Lymphoma Pathologic Classification Project. A National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
22. Stansfeld AG, Diebold AJ, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-293.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Royston P. A strategy for modeling the effect of a continuous covariate in medicine. Stat Med. 2000;30:1831-1847.
25. Cox DR. Regression models and life tables. JR Stat Soc. 1972;34:187-220.
26. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
27. Solal-Céligny P, Lepage E, Brousse N, et al. Doxorubicin containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol. 1998;16:2332-2338.
28. McLaughlin P, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy for relapsed indolent B-cell lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
29. Dillman RO. Radiolabeleded anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002;20:3545-3557.
30. Hunault-Berger M, Ifrah N, Solal-Céligny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood. 2002;100:1141-1152.
31. Khouri IF, Saliba RM, Giralt SA, et al. Non-ablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease and treatment-related mortality. Blood. 2001;98:3584-3588.
32. Czuczman M, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
33. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71-75.
34. Schultze J, Nadler LM. T-cell mediated immunotherapy for B-cell lymphoma. J Mol Med. 1999;77:322-331.